GlobeNewswire Inc.··Rosen Law FirmImmutep Stock Collapses 82.6% After Failed Phase III Trial, Triggering Class Action
Immutep shares plummet 82.6% after discontinuing Phase III trial for eftilagimod alfa due to futility, triggering class action investigation by Rosen Law Firm.
IMMPinvestor lossessecurities class action